Silverfin false false 31/03/2025 01/04/2024 31/03/2025 William Richard Brown 17/12/2010 Michael Julian 21/01/2016 Justin Charles Retallack 17/12/2010 13 October 2025 The principal activity of the Company during the financial years was the development, manufacture and sale of serum0free and ready-to-use in vitro fertilisation (IVF) media for animal reproduction. 07121405 2025-03-31 07121405 bus:Director1 2025-03-31 07121405 bus:Director2 2025-03-31 07121405 bus:Director3 2025-03-31 07121405 2024-03-31 07121405 core:CurrentFinancialInstruments 2025-03-31 07121405 core:CurrentFinancialInstruments 2024-03-31 07121405 core:Non-currentFinancialInstruments 2025-03-31 07121405 core:Non-currentFinancialInstruments 2024-03-31 07121405 core:ShareCapital 2025-03-31 07121405 core:ShareCapital 2024-03-31 07121405 core:RetainedEarningsAccumulatedLosses 2025-03-31 07121405 core:RetainedEarningsAccumulatedLosses 2024-03-31 07121405 core:OtherResidualIntangibleAssets 2024-03-31 07121405 core:OtherResidualIntangibleAssets 2025-03-31 07121405 core:PlantMachinery 2024-03-31 07121405 core:OfficeEquipment 2024-03-31 07121405 core:PlantMachinery 2025-03-31 07121405 core:OfficeEquipment 2025-03-31 07121405 bus:OrdinaryShareClass1 2025-03-31 07121405 2024-04-01 2025-03-31 07121405 bus:FilletedAccounts 2024-04-01 2025-03-31 07121405 bus:SmallEntities 2024-04-01 2025-03-31 07121405 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 07121405 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 07121405 bus:Director1 2024-04-01 2025-03-31 07121405 bus:Director2 2024-04-01 2025-03-31 07121405 bus:Director3 2024-04-01 2025-03-31 07121405 core:OtherResidualIntangibleAssets core:TopRangeValue 2024-04-01 2025-03-31 07121405 core:PlantMachinery core:TopRangeValue 2024-04-01 2025-03-31 07121405 core:OfficeEquipment core:TopRangeValue 2024-04-01 2025-03-31 07121405 2023-04-01 2024-03-31 07121405 core:OtherResidualIntangibleAssets 2024-04-01 2025-03-31 07121405 core:PlantMachinery 2024-04-01 2025-03-31 07121405 core:OfficeEquipment 2024-04-01 2025-03-31 07121405 core:Non-currentFinancialInstruments 2024-04-01 2025-03-31 07121405 bus:OrdinaryShareClass1 2024-04-01 2025-03-31 07121405 bus:OrdinaryShareClass1 2023-04-01 2024-03-31 iso4217:GBP xbrli:pure xbrli:shares

Company No: 07121405 (England and Wales)

# IVF LIMITED

### Unaudited Financial Statements
For the financial year ended 31 March 2025
Pages for filing with the registrar

IVF LIMITED

## Unaudited Financial Statements

For the financial year ended 31 March 2025

Contents

IVF LIMITED

## STATEMENT OF FINANCIAL POSITION

As at 31 March 2025
IVF LIMITED

## STATEMENT OF FINANCIAL POSITION (continued)

As at 31 March 2025

| Note | 2025 |  | 2024
|  | £ |  | £
Fixed assets |  |  |  |
Intangible assets | 3 | 38,563 |  | 42,221
Tangible assets | 4 | 12,745 |  | 13,172
|  | 51,308 |  | 55,393
Current assets |  |  |  |
Stocks |  | 127,906 |  | 106,495
Debtors | 5 | 94,279 |  | 155,573
Cash at bank and in hand |  | 127,510 |  | 82,540
|  | 349,695 |  | 344,608
Creditors: amounts falling due within one year | 6 | ( 64,150) |  | ( 45,263)
Net current assets |  | 285,545 |  | 299,345
Total assets less current liabilities |  | 336,853 |  | 354,738
Creditors: amounts falling due after more than one year | 7 | ( 939,486) |  | ( 989,485)
Net liabilities |  | ( 602,633) |  | ( 634,747)
Capital and reserves |  |  |  |
Called-up share capital | 8 | 100 |  | 100
Profit and loss account |  | ( 602,733 ) |  | ( 634,847 )
Total shareholders' deficit |  | ( 602,633) |  | ( 634,747)

For the financial year ending 31 March 2025 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the Company to obtain an audit of its financial statements for the financial year in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements; and
- These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime and a copy of the Statement of Income and Retained Earnings has not been delivered.

The financial statements of IVF Limited (registered number: 07121405) were approved and authorised for issue by the Board of Directors on 13 October 2025. They were signed on its behalf by:

William Richard Brown Director |

IVF LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2025
IVF LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2025

##### 1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

##### General information and basis of accounting

IVF Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Bickland Industrial Park, Falmouth, TR11 4TA, United Kingdom.
The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.
The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

##### Going concern

The directors have assessed the Statement of Financial Position and likely future cash flows at the date of approving these financial statements. The directors note that the business has net liabilities of £602,633. The Company is supported through loans from the directors. The directors have confirmed that the loan facilities will continue to be available for at least 12 months from the date of signing these financial statements and the directors will continue to support the Company. Given the current position, the directors believe that any foreseeable debts can be met for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

##### Foreign currency

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Statement of Financial Position date are reported at the rates of exchange prevailing at that date.
Exchange differences are recognised in the Statement of Income and Retained Earnings in the period in which they arise except for exchange differences arising on gains or losses on non-monetary items which are recognised in the Statement of Comprehensive Income.

##### Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.
Turnover is recognised when the significant risks and rewards are considered to have been transferred to the customer.

##### Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Statement of Financial Position date.

##### Intangible assets

Intangible assets are stated at cost or valuation, net of amortisation and any provision for impairment. Amortisation is provided on all intangible assets at rates to write off the cost or valuation of each asset over its expected useful life as follows:

Other intangible assets | 20 years straight line

##### Tangible fixed assets

Tangible fixed assets are stated at cost (or deemed cost) or valuation less accumulated depreciation and accumulated impairment losses. Cost includes costs directly attributable to making the asset capable of operating as intended. Depreciation is provided on all tangible fixed assets, other than investment properties and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line basis over its expected useful life, as follows:

Plant and machinery | 10 years straight line
Office equipment | 10 years straight line

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.
Land and buildings were valued at [input date]. The valuation was undertaken by [input name] and qualification on the [input detail basis.]

##### Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Statement of Financial Position date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Income and Retained Earnings as described below.

##### Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to sell, which is equivalent to the net realisable value. Cost includes materials, direct labour and an attributable proportion of manufacturing overheads based on normal levels of activity. Cost is calculated using the FIFO (first-in, first-out) method. Provision is made for obsolete, slow-moving or defective items where appropriate.
At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

##### Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts, except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

##### Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

##### Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

##### Ordinary share capital

The ordinary share capital of the Company is presented as equity.

#### 2. Employees

| 2025 |  | 2024
| Number |  | Number
Monthly average number of persons employed by the Company during the year, including directors | 3 |  | 3

#### 3. Intangible assets

| Other intangible assets |  | Total
| £ |  | £
Cost |  |  |
At 01 April 2024 | 73,168 |  | 73,168
At 31 March 2025 | 73,168 |  | 73,168
Accumulated amortisation |  |  |
At 01 April 2024 | 30,947 |  | 30,947
Charge for the financial year | 3,658 |  | 3,658
At 31 March 2025 | 34,605 |  | 34,605
Net book value |  |  |
At 31 March 2025 | 38,563 |  | 38,563
At 31 March 2024 | 42,221 |  | 42,221

#### 4. Tangible assets

| Plant and machinery |  | Office equipment |  | Total
| £ |  | £ |  | £
Cost |  |  |  |  |
At 01 April 2024 | 25,893 |  | 9,038 |  | 34,931
Additions | 542 |  | 2,641 |  | 3,183
At 31 March 2025 | 26,435 |  | 11,679 |  | 38,114
Accumulated depreciation |  |  |  |  |
At 01 April 2024 | 16,109 |  | 5,650 |  | 21,759
Charge for the financial year | 2,635 |  | 975 |  | 3,610
At 31 March 2025 | 18,744 |  | 6,625 |  | 25,369
Net book value |  |  |  |  |
At 31 March 2025 | 7,691 |  | 5,054 |  | 12,745
At 31 March 2024 | 9,784 |  | 3,388 |  | 13,172

#### 5. Debtors

| 2025 |  | 2024
| £ |  | £
Trade debtors | 61,460 |  | 55,350
Deferred tax asset | 23,859 |  | 86,935
Other debtors | 8,960 |  | 13,288
| 94,279 |  | 155,573

#### 6. Creditors: amounts falling due within one year

| 2025 |  | 2024
| £ |  | £
Trade creditors | 23,358 |  | 22,263
Other taxation and social security | 10,427 |  | 10,748
Other creditors | 30,365 |  | 12,252
| 64,150 |  | 45,263

#### 7. Creditors: amounts falling due after more than one year

| 2025 |  | 2024
| £ |  | £
Other creditors | 939,486 |  | 989,485

There are no amounts included above in respect of which any security has been given by the small entity.

#### 8. Called-up share capital

| 2025 |  | 2024
| £ |  | £
Allotted, called-up and fully-paid |  |  |
1,000 Ordinary shares of £ 0.10 each | 100 |  | 100

#### 9. Related party transactions

Transactions with the entity's directors

| 2025 |  | 2024
| £ |  | £
Amounts owed to directors | 939,486 |  | 989,485

Amounts owed to directors are included within creditors due after 1 year. These balances are interest free and have no fixed date for repayment.